Phio Pharmaceuticals Corp. carries no debt; cash flow comfortably covers obligations.

Phio Pharmaceuticals Corp.'s free cash flow has decreased 12.34% from $-7.11M last year to $-7.99M, signaling decreasing performance

Phio Pharmaceuticals Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Phio Pharmaceuticals Corp. has insufficient data to evaluate this check.

Phio Pharmaceuticals Corp. has negative EBITDA, making leverage ratio unreliable

Phio Pharmaceuticals Corp. carries no debt; interest obligations are fully covered.

Phio Pharmaceuticals Corp. has insufficient data to evaluate this check.

Phio Pharmaceuticals Corp.'s short-term assets of $21.48M exceed its short-term liabilities of $435.00K

Phio Pharmaceuticals Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Phio Pharmaceuticals Corp.'s return on equity of -77.34%, is lower than 15.00%, indicating bad performance

Phio Pharmaceuticals Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Phio Pharmaceuticals Corp. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Phio Pharmaceuticals Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Phio Pharmaceuticals Corp. has negative free cash flow, indicating cash burn

Phio Pharmaceuticals Corp.'s yearly earnings has decreased 21.65% since last year from $-7.15M to $-8.70M, signaling decreasing performance

Phio Pharmaceuticals Corp.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -67.14% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Phio Pharmaceuticals Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

Phio Pharmaceuticals Corp. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Phio Pharmaceuticals Corp. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Phio Pharmaceuticals Corp. has insufficient data to evaluate this check.

Phio Pharmaceuticals Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Phio Pharmaceuticals Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Phio Pharmaceuticals Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Phio Pharmaceuticals Corp. has insufficient data to evaluate this check.

Phio Pharmaceuticals Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Phio Pharmaceuticals Corp. has a price-to-book ratio of 0.73x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Phio Pharmaceuticals Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue